A team of military doctors and scientists are developing a technology known as the TXA Autoinjector, which will help stop rapid blood loss on the battlefield.
UK Defence Secretary Gavin Williamson granted a £5m transformation fund to the TXA Autoinjector project to accelerate the technology.
Williamson said: “Saving lives is at the heart of what our armed forces do, and this funding shows our commitment to ensuring those serving on the frontline get the best treatment as rapidly as possible.
“Our work to save lives does not stop at our serving men and women but must also be about helping to improve the livelihoods of people across the world. This technology will allow us to just that, whether it is rolling it out to emergency services in the UK, or equipping medics in developing countries across the globe.”
Once the technology is tested, it could be adapted from use in the battlefield to any major trauma incidents.
TXA Autoinjector should be administered as soon as possible after an injury.
Injured soldiers can pack the drug into a pre-filled AutoInjector and can self-treat as part of their first aid drills. They do not have to wait for the arrival of evacuation or specialist medical help.
The auto-injector uses a cost-effective drug known as tranexamic acid that stabilises and strengthens blood clotting within damaged tissues. It can be administered by an untrained user.
With the development of the new technology, TXA can be administered safely into a muscle.
Treatment using TXA Autoinjector is expected to be beneficial for up to a third of soldiers who are seriously injured.
Once developed, the Autoinjector is planned to be rolled out to police, non-government organisations, ambulance services, and Code Red first aid kits in public places.